Clinical trial NCT03855696: A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients
Official title: A Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MG1113 in Healthy Subjects and Hemophilia Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hemophilia
Keywords: MG1113
Hemophilia
Lead sponsor: GC Biopharma Corp
Sponsor class: INDUSTRY
Collaborators: name: Dream CIS, Inc.
First posted: 2019-02-27
Enrollment: 41
Sex: MALE
Minimum age (years): 19
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Sequential dose escalation model
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess the safety and tolerability of MG1113 in the single ascending dose study (IV injection or SC injection) in healthy subjects and hemophiia patients.

Detailed description: This is a single-dose study that explore the safety, tolerability, PK, and PD of the study drug by sequentially increasing the study drug in 4 dose levels. The route of administration is either subcutaneous (SC) injection or intravenous (IV) injection.

For healthy subjects, 6 subjects will be assigned to the study group and 2 subjects will be assigned to the placebo group to explore the safety and tolerability, and PK/PD of the study drug in comparison with placebo. Hemophilia patients will be assigned only to the study group with 3 and 6 subjects in each cohort, respectively.

The investigator and subjects will know which cohort the healthy subjects have been assigned to, but they will be double-blinded as to whether the subjects are assigned to the study group (study drug) or the placebo group (placebo) within each cohort.

The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg by IV injection. In hemophilia patients, 1.7 mg/kg and 3.3 mg/kg will be administered by SC injection. The planned dose will be administered after checking the safety and tolerability at the previous dose to the extent not exceeding the criteria for discontinuation of dose escalation. The dose escalation will be decided by the Data Monitoring Committee(DMC) and Data and Safety Monitoring Boards (DSMB) in the blinded evaluation of the safety and tolerability data obtained from each previous cohort for 7 days after administration. Before deciding dose escalation and proceeding to the next step, the safety, tolerability, PK, and PD data obtained from all healty subjects and hemophilia patients up to cohort 6 will be evaluated by the Data and Safety Monitoring Boards (DSMB) in an unblinded manner. In addition, if necessary, the analysis result of cohort that has completed all the scheduled visits can be reviewed in an unblinded manner.

Eligibility criteria: \<Healthy adult subjects\>

* Inclusion Criteria:

  1. Healthy male adult subjects aged 19-60 years (both inclusive) at screening
  2. 50 to 90 kg in weight with calculated BMI between 18.5 and 29.9 kg/m2
  3. Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 3 months after administration of the investigational product
  4. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information
* Exclusion Criteria:

  1. Presence or history of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immune, skin, nervous, or psychiatric disease
  2. Symptoms of acute disease within 28 days of investigational product administration
  3. Medical history that may affect absorption, distribution, metabolism and excretion of drugs
  4. Clinically significant active chronic disease
  5. Clinically significant allergic disease (however, mild allergic rhinitis or allergic dermatitis not requiring any medication is allowed) or history of any anaphylactic reaction
  6. Any of the following results from laboratory tests: 1) AST (sGOT) or ALT (sGPT) \>2 x UNL 2) Hb \< 9.0 g/dL 3) Absolute Neutrophil Count \< 1500 mm2 4) Platelet count \< 100 x 103 mm2 5) aPTT, PT \> 1.5 x UNL 6) Have hepatitis B (HBsAg positive) or C (anti-HCV positive), or have positive HIV test result 7) Creatinine clearance ≤80 mL/min (calculated by the Cockcroft-Gault formula)
  7. Have a family history or be considered to be at risk of thromboembolic events, or have the following test results: 1) Antithrombin level ≤LNL 2) Protein C or S activity ≤LNL 3) Factor V Leiden mutation 4) Prothrombin G20210A mutation
  8. Used ethical drugs including prescription drugs within 14 days of investigational product administration
  9. Used drugs (over-the-counter drugs, herbal medicines, and nutritional agents and vitamins for the purpose of same efficacy) within 7 days of investigational product administration
  10. Cannot have standard meals provided at the hospital
  11. Donated whole blood within 60 days of investigational product administration, or donated blood components within 20 days of investigational product administration, or received blood transfusion within 1 month before administration
  12. Participated in another clinical trial or bioequivalence study within 90 days of investigational product administration (If participating in a clinical trial after 12/06/2019, not within 90 days, but within 6 months is applied)
  13. Individuals who consume caffeine (caffeine \>5 cups/day) or alcohol (alcohol \>30 g/day) continuously, who cannot abstain from drinking during the study, or heavy smoker (\>10 cigarettes/day)
  14. Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results
  15. History of drug abuse or positive urine drug screen results

\<Hemophilia patients\>

* Inclusion criteria

  1. Male hemophilia A or B patients aged 19-60 years (both inclusive) at screening
  2. ≥50 kg in weight with calculated BMI between 18.5 and 29.9 kg/m2
  3. Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 60 days after administration of the investigational product
  4. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information
* Exclusion criteria

  1. Symptoms of acute disease within 28 days of investigational product administration or any surgery planned during the study period
  2. Medical history that may affect absorption, distribution, metabolism and excretion of drugs
  3. Clinically significant active chronic disease
  4. Clinically significant allergic disease (however, mild allergic rhinitis or allergic dermatitis not requiring any medication is allowed) or history of any anaphylactic reaction
  5. Patients having current human factor VIII or IX with an inhibitor titer of \>5 Bethesda units or patients requiring treatment with bypassing agent
  6. Patients who has a history of confirmed human factor VIII or IX with an inhibitor titer of \>5 Bethesda units at any time
  7. History of ≥6 bleeding episodes despite temporary bypassing agent administered for 24 weeks before screening, or ≥2 bleeding episodes despite the bypassing agent administered prophylactically
  8. Received factor VIII or factor IX within 48 hours prior to administration of the investigational product
  9. Hemostatic agent, etc. prescribed to control bleeding within 5 days prior to administration of the investigational product
  10. Immune tolerance induction prescribed within 30 days prior to administration of the investigational product
  11. Currently using systemic immunomodulator (e.g., interferon or rituximab)
  12. Be at risk of thrombotic microangiopathy per investigator's judgment or have related medical history or family history
  13. Congenital or acquired anticoagulant disorders other than hemophilia A or B, or conditions of other diseases that increase the risk of bleeding or thrombus (e.g., autoimmune disease)
  14. Any of the following results from laboratory tests: 1) AST (sGOT) or ALT (sGPT) \>3 x UNL 2) Hb \< 9.0 g/dL 3) Absolute Neutrophil Count \< 1500 mm2 4) Platelet count \< 100 x 103 mm2 5) Have hepatitis B (HBs Ag positive) or C (anti-HCV positive), or have HIV positive test result 6) Creatinine clearance ≤80 mL/min (calculated by the Cockcroft-Gault formula)
  15. Cannot have standard meals provided at the hospital
  16. Participated in another clinical trial within 90 days of investigational product administration
  17. Individuals who consume caffeine (caffeine \>5 cups/day) or alcohol (alcohol \>30 g/day) continuously, who cannot abstain from drinking during the study, or heavy smoker (\>10 cigarettes/day)
  18. Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results
  19. History of drug abuse or positive urine drug screen results

Primary outcomes:
measure: Adverse events
timeFrame: Through study completion (~50 day)
Secondary outcomes:
measure: Immunogenicity assay
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - Cmax
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - Tmax
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - AUClast
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - AUCinf
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - half-life
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - CL/F (for SC)
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - CL (for IV)
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - Vd/F (for SC)
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - Vd (for IV)
timeFrame: Through study completion (~50 day)
measure: Pharmacokinetic assessment - Bioavailability (F)
timeFrame: Through study completion (~50 day)
measure: Pharmacodynamic assessment - Free TFPI in plasma
timeFrame: Through study completion (~50 day)
measure: Pharmacodynamic assessment - Diluted PT
timeFrame: Through study completion (~50 day)
measure: Pharmacodynamic assessment - residual TFPI activity
timeFrame: Through study completion (~50 day)
measure: Pharmacodynamic assessment - Thrombin generation
timeFrame: Through study completion (~50 day)
measure: Pharmacodynamic assessment - Pro-coagulant effect
timeFrame: Through study completion (~50 day)
measure: Physical examination
timeFrame: Through study completion (~50 day)
measure: Incidence of participant abnormalities in 12-lead ECG (Ventricular rate in beat/min, Interval for PR in msec, QRS in msec, QTc in msec) for physiological parameter
timeFrame: Through study completion (~50 day)
measure: Vital signs - blood pressure (Systolic, Diastolic)
timeFrame: Through study completion (~50 day)
measure: Vital signs - pulse rate
timeFrame: Through study completion (~50 day)
measure: Vital signs - body temperature
timeFrame: Through study completion (~50 day)
measure: Frequency of Bleeding (only for hemophilia patients)
timeFrame: Through study completion (~50 day)
measure: Local reaction in injection site
timeFrame: Through study completion (~50 day)
measure: Incidence of participant abnormalities in laboratory tests by physiological parameter (Hematology, clinical chemistry, urinalysis, and blood coagulation test)
timeFrame: Through study completion (~50 day)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei Cancer Center, Yonsei University Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
Study officials:
affiliation: Korea University Anam Hospital
name: Ji-Young Park, MD
role: PRINCIPAL_INVESTIGATOR
References: